EPIRUS Biopharmaceuticals
EPRSQ
EPRSQ
A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.
Interactive Chart
News & Analysis: EPIRUS Biopharmaceuticals
"Better Than Nothing" Doesn't Cut It for Zalicus
Zalicus' Synavive beats placebo, but not an active comparator.
Pain-Free Pipeline Progress
Zalicus moves its nerve-pain drug into phase 2 development.
New Dosage Boosts Zalicus
Zalicus announces FDA approval of 32 milligram dose of Exalgo.
Wall Street Loves These Stocks. Should You?
Analysts are unanimously bullish, but do you agree with these Wall Street darlings?
Stocks Shaking the Investment World
These stocks caused the markets to tremble this past month.
Making Cents in Penny Stocks
A low price doesn't always mean low quality.
There's a BOGO Sale on These Top Stocks
Investors still think highly of these companies, despite their fire-sale prices.
Stocks on the Road to Greatness
Investors can find great investments by looking beyond the glare of top-rated stars.
Top Stocks at Half-Price
Investors still think highly of these companies, despite their fire-sale prices.
